In the realm of HIV prevention, the emergence of long-acting injectable PrEP (pre[1]exposure prophylaxis) has marked a significant advancement. Dr. Nyaradzo Mavis Mgodi, a seasoned clinical pathologist with extensive experience in HIV clinical trials among women in sub-Saharan Africa, sheds light on the efficacy, safety, and challenges associated with long-acting PrEP and cabotegravir roll-out. In a recent interview following her presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023, Dr. Mgodi provides insightful perspectives on these critical developments.